Augsburg

• ABTECT-2 – ABX464 Treatment Evaluation for ulcerative Colitis Therapy -2 Not authorised
  2022-500536-11-00 5 Moderately to severely active ulcerative colitis
• ABTECT-Maintenance – ABX464 Treatment Evaluation for ulcerative Colitis Therapy Not authorised
  2022-500537-84-00 5 Moderately to severely active ulcerative colitis
• A randomised, controlled trial to investigate the effect of a four/six week intensified pharmacological treatment for schizophrenia, major d … Not authorised
  2022-502185-24-00 5 Schizophrenia, schizoaffective disorder, schizophreniform disorder, ma
• A one-year study to assess if Xanomeline/Trospium (XT) can improve cognitive function in adults living with schizophrenia. Not authorised
  2025-523060-20-00 5 Schizophrenia
• Randomised efficacy and safety clinical trial of PQ Birch in subjects with seasonal allergic rhinitis and/or rhinoconjunctivitis induced by … Pending
  2023-507427-28-00 5 seasonal allergic rhinitis and/or rhinoconjunctivitis
• Clinical trial to determine the efficacy and safety of AP707 in the treatment of Borderline Personality Disorder Pending
  2024-510873-11-00 4 Borderline personality disorder
• SIOP PNET 5 medulloblastoma Pending
  2024-513724-42-00 10 Medulloblastoma
• A study to evaluate the efficacy of oxaliplatin- or gemcitabine-based chemotherapy after allocation by standard criteria or by genetic marke … Pending
  2024-514682-19-00 5 Resected pancreatic ductal adenocarcinoma
• BEACON 2: A Multi-Arm, Multi-Stage Platform Trial For Relapsed Neuroblastoma Pending
  2024-516115-24-00 9 High risk relapsed neuroblastoma (relapsed or progressed after being d
• NeoAdjuvant Dynamic marker - Adjusted Personalized Therapy comparing sacituzumab govitecan+pembrolizumab vs. SoC chemotherapy in clinical st … Pending
  2024-516734-35-00 5 triple-negative early breast cancer
• Phase I/II combination umbrella trial in progressive/relapsed/refractory pediatric low-grade glioma (pLGG) (EPILOGUE) Pending
  2024-516896-34-00 9 progressive/relapsed/refractory pediatric low-grade glioma (pLGG)
• Comparison of neurocognitive outcome in two standard regimen for treatment of low-risk medulloblastoma (COGNITO-MB) Pending
  2024-517133-40-00 5 newly diagnosed, non-metastatic, SHH-activated, TP53-wt, non-MYC ampli
• Prospective multicenter clinical trial for risk estimation and treatment stratification in low and intermediate risk neuroblastoma patients … Pending
  2024-517295-37-00 5 low and intermediate risk neuroblastoma
• A Phase 1/2, First-in-Human Study to Assess the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Anti_Tumor Activity of AVZO-02 … Pending
  2024-517339-30-00 7 Advanced Solid Tumors
• CHEMOKINE RECEPTOR CXCR4-DIRECTED THERANOSTICS OF ADVANCED LYMPHOPROLIFERATIVE CANCERS BY RADIOPEPTIDE-BASED IMAGING AND THERAPY: THE COLPRI … Pending
  2024-517639-35-00 9 Non-Hodgkin lymphomas (NHL)
• Durvalumab (MEDI4736) in combination with consolidative radiochemotherapy and ablative stereotactic radiotherapy in extensive stage SCLC Pending
  2024-517937-41-00 4 extensive stage small cell lung cancer (SCLC)
• Dehydroepiandrosterone (DHEA) as augmentation of standard antidepressants in treatment-resistant depression: a randomized controlled trial ( … Pending
  2024-517963-21-00 5 Treatment Resistant Depression (TRD)
• A clinical trial to learn about the long-term safety of FUB523 (zigakibart) in people with immunoglobulin A (IgA) nephropathy who have compl … Pending
  2024-519638-22-00 5 IgA nephropathy
• A Study to Evaluate the Efficacy and Safety of IMG-007 in Adult Participants with Moderate-to-Severe Atopic Dermatitis (ADAPTIVE) Pending
  2024-520117-50-00 4 Atopic Dermatitis
• Revumenib Treatment in Combination with FLA Chemotherapy in Paediatric Refractory/Relapsed KMT2A-r, NUP98-r or NPM1-mut Acute Myeloid Leukem … Pending
  2025-521390-14-00 4 Acute Myeloid Leukemia
• A Study of Pumitamig Versus Durvalumab Following Concurrent Chemoradiation Therapy in Participants with Unresectable Stage III NSCLC Pending
  2025-523576-23-00 5 Unresectable Stage III non-small cell lung cancer without progression
• A multiCenter phase I study of aUtologous CD19 CAR T cElls for therapy refractory chronic GvHD (CURE-cGvHD) Pending
  2025-524468-40-00 3 chronic Graft-versus-Host-Disease (cGvHD)
• Adjuvant Dynamic marker - Adjusted Personalized Therapy comparing adjuvant Elacestrant with standard endocrine treatment in genomically and/ … Recruiting
  2025-522484-15-00 5 2026-04-27 ER+/HER2- early breast cancer
• L19IL2 or L19TNF or L19IL2/TNF in patients with basal cell carcinoma (BCC) Recruiting
  2025-523229-16-00 4 2026-04-27 locally advanced basal cell carcinoma patients

Showing 1–24 of 283 trials